By treating kinase inhibitors of the SRPK, CLK, and DYRK families, such as TG-003 and SRPIN340 (Table 2), reduced phosphorylation of SR proteins was linked to an AS-coupled NMD mechanism that contributes to reduced SRSF2, FAS, and VEGF transcripts in distinct cancer cells [78,79,80,84]. The gene discussed is CLK1; the disease is cancer.